Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 17/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 17/20 | 0.71 |
| ▸ | VNN1 | O95497 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18742710 | 0.87 | HDAC3 (0.76) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL14937075 | 0.84 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL8738690 | 0.83 | HDAC3 (1.00) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL8739601 | 0.82 | HDAC3 (1.00) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL18742702 | 0.82 | HDAC3 (0.79) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL14937072 | 0.81 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL18742555 | 0.81 | HDAC6 (0.63) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL4729663 | 0.80 | HDAC3 (1.00) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL18742510 | 0.80 | HDAC6 (0.68) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL18742748 | 0.80 | HDAC3 (0.68) | HDAC6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3698795-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3698795-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-9018223-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8962632-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962632-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962632-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | HDAC6 2861/4885HDAC3 3047/4885HDAC1 1672/4885 |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | HDAC6 2667/4885HDAC3 3180/4885HDAC1 2308/4885 |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | HDAC6 2667/4885HDAC3 3180/4885HDAC1 2308/4885 |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | HDAC6 2861/4885HDAC3 3047/4885HDAC1 1672/4885 |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | HPRT1, TYMP, TYMS | HDAC6 3656/4885HDAC3 4217/4885HDAC1 3791/4885 |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | HPRT1, TYMP, TYMS | HDAC6 3656/4885HDAC3 4217/4885HDAC1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.